Warrant Issuances	12 Months Ended
Dec. 31, 2014
Warrant Liabilities [Abstract]
Warrant Liabilities [Text Block]	11. Warrant Issuances As part of the Company’s debt restructuring plan in 2011 the Company issued 166,600 one-year warrants (the “A Warrants”). The expiration date of the A Warrants was subsequently extended until September 13, 2013, at which time 161,200 unexercised A Warrants expired. Each A Warrant entitled the holder to purchase one share of the Company’s Common Stock and a three-year warrant (the “B Warrants”), at an exercise price of $5.00 per share. 5,400 A Warrants were exercised before the expiration, resulting in the issuance of 5,400 B Warrants. As a result of the Retop investment (see Note 14 – Securities Purchase Agreement for Common Stock) and the repricing clause in the B Warrant agreement, there were 11,250 B Warrants that each entitled the holder to purchase one share of the Company’s Common Stock at an exercise price of $6.00 per share, which expired unexercised on November 11, 2014. In connection with an offering of Series A Convertible Preferred Stock in 2011, the Company issued 48,000 three-year warrants to the Placement Agent (the “Placement Agent Warrants”). As a result of the Retop investment (see Note 14 – Securities Purchase Agreement for Common Stock) and the repricing clause in the Placement Agent Warrant agreement, the 48,000 warrants converted into 100,000 warrants exercisable at a price of $6.00 per share. Upon the exercise of these Placement Agent Warrants, the Company would have issued 9,600 A Warrants to the Placement Agent and upon the exercise of these A Warrants, the Company would have issued 9,600 B Warrants to the Placement Agent. The aggregate number of Placement Agent Warrants, A Warrants and B Warrants to which the Placement Agent was entitled was 119,200. Each Placement Agent Warrant entitled the Placement Agent to purchase one share of the Company’s Common Stock at an exercise price of $6.00 per share and a two-year A Warrant. Each A Warrant, which, if issued, would have expired on November 14, 2016, would have entitled the Placement Agent to purchase one share of the Company’s Common Stock and a three-year B Warrant at an exercise price of $5.00 per share. Each B Warrant, which, if issued, would have expired on November 14, 2017, would have entitled the Placement Agent to purchase one share of the Company’s Common Stock at an exercise price of $12.50 per share. On November 14, 2014, the Placement Agent Warrants expired unexercised, and accordingly the underlying A and B Warrants were never issued. In connection with a private placement of $650,000 of 4.00% notes, see Note 12 – Long-Term Debt, the Company issued 40,000 warrants to the subscriber at an exercise price of $2.50 per share, which would have expired on June 17, 2016. These warrants were exercised in October 2014. The foregoing warrants included potential adjustments of the strike prices if the Company sold or granted any option or warrant at a price per share less than the strike prices of the warrants. Therefore, these warrants were not considered indexed to the Company’s Common Stock and were accounted for on a liability basis. The Company recorded a non-cash charge of $107,000 in 2014 and a non-cash gain of $1.1 million in 2013 related to changes in the value of the warrants issued in the Offering, the Placement Agent and the subscriber in connection with the $650,000 of 4.00% secured notes, which is included in a separate line item, Change in warrant liabilities, in the Consolidated Statements of Operations. On June 11, 2013, the Company entered into a Master Agreement for Sale and Assignment of Leases with AXIS Capital, Inc. (the “Assignment Agreement”) and financed the future receivables relating to certain lease contracts. In connection with the Assignment Agreement, the Company issued warrants to purchase 7,200 shares of the Company’s Common Stock, par value $0.001, to AXIS Capital, Inc. at an exercise price of $12.50 per share. The issuance of the warrants was completed in accordance with the exemption provided by Section 4(2) of the Securities Act of 1933, as amended. These warrants do not include a potential adjustment of the strike price if the Company sells or grants any options or warrants at a price per share less than the strike price of the warrants, so they are considered indexed to the Company’s Common Stock and were accounted for as equity. These warrants expired unexercised on June 11, 2014. In November 2012, the Board of Directors approved the issuance to two board members, George W. Schiele and Salvatore J. Zizza, of warrants to purchase 20,000 shares of Common Stock at an exercise price of $12.50 per share. In April 2013, the Board of Directors approved the issuance to one board member, Jean Firstenberg, of warrants to purchase 2,000 shares of Common Stock at an exercise price of $12.50 per share. Each of these warrant issuances was approved by shareholders at the Company’s 2013 Annual Meeting of Shareholders on October 2, 2013. The warrants were issued effective October 2, 2013, began to vest after one year and expire on October 2, 2018. The Company recorded non-cash expenses of $150,000 and $21,000 in the years ended December 31, 2014 and 2013, respectively, related to the value of the warrants issued, which is included in Change in warrant liabilities and other warrant expense in the Consolidated Statements of Operations. These warrants do not include a potential adjustment of the strike price if the Company sells or grants any options or warrants at a price per share less than the strike price of the warrants, so they are considered indexed to the Company’s Common Stock and were accounted for as equity. On June 27, 2014, the Company entered into a Securities Purchase Agreement (the “SPA”) with Retop Industrial (Hong Kong) Limited (“Retop”), pursuant to which Retop purchased 333,333 shares of the Company’s Common Stock, par value $0.001 per share, for a purchase price of $2,000,000 (the “Purchase”). The SPA requires that the proceeds of the Purchase are to be utilized solely in connection with the Company’s LED display business unit, including for working capital and general corporate purposes related thereto. In connection with the SPA, the Company issued warrants to purchase 33,333 shares of the Company’s Common Stock to Retop at an exercise price of $8.00 per share, which expire on June 27, 2016. These warrants were part of a direct investment in our equity, so they are considered indexed to the Company’s Common Stock and were accounted for as equity.

Warrant Issuances

12 Months Ended

Dec. 31, 2014

11. Warrant Issuances

As part of the Company’s debt restructuring plan in 2011 the Company issued 166,600 one-year warrants (the “A Warrants”). The expiration date of the A Warrants was subsequently extended until September 13, 2013, at which time 161,200 unexercised A Warrants expired. Each A Warrant entitled the holder to purchase one share of the Company’s Common Stock and a three-year warrant (the “B Warrants”), at an exercise price of $5.00 per share. 5,400 A Warrants were exercised before the expiration, resulting in the issuance of 5,400 B Warrants. As a result of the Retop investment (see Note 14 – Securities Purchase Agreement for Common Stock) and the repricing clause in the B Warrant agreement, there were 11,250 B Warrants that each entitled the holder to purchase one share of the Company’s Common Stock at an exercise price of $6.00 per share, which expired unexercised on November 11, 2014.

In connection with an offering of Series A Convertible Preferred Stock in 2011, the Company issued 48,000 three-year warrants to the Placement Agent (the “Placement Agent Warrants”). As a result of the Retop investment (see Note 14 – Securities Purchase Agreement for Common Stock) and the repricing clause in the Placement Agent Warrant agreement, the 48,000 warrants converted into 100,000 warrants exercisable at a price of $6.00 per share. Upon the exercise of these Placement Agent Warrants, the Company would have issued 9,600 A Warrants to the Placement Agent and upon the exercise of these A Warrants, the Company would have issued 9,600 B Warrants to the Placement Agent. The aggregate number of Placement Agent Warrants, A Warrants and B Warrants to which the Placement Agent was entitled was 119,200. Each Placement Agent Warrant entitled the Placement Agent to purchase one share of the Company’s Common Stock at an exercise price of $6.00 per share and a two-year A Warrant. Each A Warrant, which, if issued, would have expired on November 14, 2016, would have entitled the Placement Agent to purchase one share of the Company’s Common Stock and a three-year B Warrant at an exercise price of $5.00 per share. Each B Warrant, which, if issued, would have expired on November 14, 2017, would have entitled the Placement Agent to purchase one share of the Company’s Common Stock at an exercise price of $12.50 per share. On November 14, 2014, the Placement Agent Warrants expired unexercised, and accordingly the underlying A and B Warrants were never issued.

In connection with a private placement of $650,000 of 4.00% notes, see Note 12 – Long-Term Debt, the Company issued 40,000 warrants to the subscriber at an exercise price of $2.50 per share, which would have expired on June 17, 2016. These warrants were exercised in October 2014.

The foregoing warrants included potential adjustments of the strike prices if the Company sold or granted any option or warrant at a price per share less than the strike prices of the warrants. Therefore, these warrants were not considered indexed to the Company’s Common Stock and were accounted for on a liability basis. The Company recorded a non-cash charge of $107,000 in 2014 and a non-cash gain of $1.1 million in 2013 related to changes in the value of the warrants issued in the Offering, the Placement Agent and the subscriber in connection with the $650,000 of 4.00% secured notes, which is included in a separate line item, Change in warrant liabilities, in the Consolidated Statements of Operations.

On June 11, 2013, the Company entered into a Master Agreement for Sale and Assignment of Leases with AXIS Capital, Inc. (the “Assignment Agreement”) and financed the future receivables relating to certain lease contracts. In connection with the Assignment Agreement, the Company issued warrants to purchase 7,200 shares of the Company’s Common Stock, par value $0.001, to AXIS Capital, Inc. at an exercise price of $12.50 per share. The issuance of the warrants was completed in accordance with the exemption provided by Section 4(2) of the Securities Act of 1933, as amended. These warrants do not include a potential adjustment of the strike price if the Company sells or grants any options or warrants at a price per share less than the strike price of the warrants, so they are considered indexed to the Company’s Common Stock and were accounted for as equity. These warrants expired unexercised on June 11, 2014.

In November 2012, the Board of Directors approved the issuance to two board members, George W. Schiele and Salvatore J. Zizza, of warrants to purchase 20,000 shares of Common Stock at an exercise price of $12.50 per share. In April 2013, the Board of Directors approved the issuance to one board member, Jean Firstenberg, of warrants to purchase 2,000 shares of Common Stock at an exercise price of $12.50 per share. Each of these warrant issuances was approved by shareholders at the Company’s 2013 Annual Meeting of Shareholders on October 2, 2013. The warrants were issued effective October 2, 2013, began to vest after one year and expire on October 2, 2018. The Company recorded non-cash expenses of $150,000 and $21,000 in the years ended December 31, 2014 and 2013, respectively, related to the value of the warrants issued, which is included in Change in warrant liabilities and other warrant expense in the Consolidated Statements of Operations. These warrants do not include a potential adjustment of the strike price if the Company sells or grants any options or warrants at a price per share less than the strike price of the warrants, so they are considered indexed to the Company’s Common Stock and were accounted for as equity.

On June 27, 2014, the Company entered into a Securities Purchase Agreement (the “SPA”) with Retop Industrial (Hong Kong) Limited (“Retop”), pursuant to which Retop purchased 333,333 shares of the Company’s Common Stock, par value $0.001 per share, for a purchase price of $2,000,000 (the “Purchase”). The SPA requires that the proceeds of the Purchase are to be utilized solely in connection with the Company’s LED display business unit, including for working capital and general corporate purposes related thereto. In connection with the SPA, the Company issued warrants to purchase 33,333 shares of the Company’s Common Stock to Retop at an exercise price of $8.00 per share, which expire on June 27, 2016. These warrants were part of a direct investment in our equity, so they are considered indexed to the Company’s Common Stock and were accounted for as equity.